Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Vichy mineralizing water with hyaluronic acid is effective and well tolerated as an adjunct to the management of various dermatoses and after esthetic procedures

J. Tan, J. Spada, C. Orlandi, M. Kerscher, M. Anfilova, S. Abdulla, A. Floriánová, K. Preisz, A. Altmayer, C. Delva, D. Kerob, M. Goldobina, M. Arenbergerová, S. Tuz, E. Araviiskaia,

. 2020 ; 19 (3) : 682-688. [pub] 20191203

Language English Country Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc20028453

Grant support
Laboratoires Vichy International

INTRODUCTION: M89, containing 89% of Vichy mineralizing water and hyaluronic acid, has been developed to reinforce the skin barrier and to improve skin quality. AIM: To assess efficacy and tolerability of M89. METHOD: Observational survey of subjects with facial dermatoses or after esthetic procedures. M89 served as adjunct to conventional therapy. Clinician assessments of erythema, desquamation, irritation and patient-reported dryness, burning, itching, and stinging/tingling were conducted at baseline and 4 weeks. At 1 week and 4 weeks, patient assessed tolerance and satisfaction with M89. RESULTS: A total of 1630 subjects participated; 92.5% were females. Mean age was 41.1 ± 11.3 years. Dermatological indications accounted for 32.5%, procedures for 67.5%. At 4 weeks, in subjects with dermatoses, erythema had resolved or improved in 68.0%, desquamation in 83.4%, and irritation in 93.3%. Dryness, burning, itching, and stinging/tingling scores had decreased by 63.8%, 81.8%, 70.9%, and 85.2%, respectively (all P ≤ .0001); 75.7% considered that their skin was sufficiently hydrated. In the procedure group, erythema had resolved or improved in 72.5%, desquamation in 75.2%, and irritation in 88.1%. Dryness, burning, itching, and stinging/tingling scores had decreased by 62.1%, 78.8%, 70.0%, and 84.2%, respectively (all P ≤ .0001); 74.1% considered that their skin was sufficiently hydrated. Almost all subjects reported soothed skin and satisfaction with product texture. Subject and investigator satisfaction was very high. CONCLUSION: M89 significantly improves skin signs and symptoms after 4 weeks of continued use with no tolerance issues in subjects with dermatological indications. Moreover, subjects who have had recently undergone esthetic procedures M89 allowed a satisfying skin recovery.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028453
003      
CZ-PrNML
005      
20210114153921.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jocd.13229 $2 doi
035    __
$a (PubMed)31793738
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tan, Jerry $u Schulich School of Medicine and Dentistry, Western University, Windsor, ON, Canada.
245    10
$a Vichy mineralizing water with hyaluronic acid is effective and well tolerated as an adjunct to the management of various dermatoses and after esthetic procedures / $c J. Tan, J. Spada, C. Orlandi, M. Kerscher, M. Anfilova, S. Abdulla, A. Floriánová, K. Preisz, A. Altmayer, C. Delva, D. Kerob, M. Goldobina, M. Arenbergerová, S. Tuz, E. Araviiskaia,
520    9_
$a INTRODUCTION: M89, containing 89% of Vichy mineralizing water and hyaluronic acid, has been developed to reinforce the skin barrier and to improve skin quality. AIM: To assess efficacy and tolerability of M89. METHOD: Observational survey of subjects with facial dermatoses or after esthetic procedures. M89 served as adjunct to conventional therapy. Clinician assessments of erythema, desquamation, irritation and patient-reported dryness, burning, itching, and stinging/tingling were conducted at baseline and 4 weeks. At 1 week and 4 weeks, patient assessed tolerance and satisfaction with M89. RESULTS: A total of 1630 subjects participated; 92.5% were females. Mean age was 41.1 ± 11.3 years. Dermatological indications accounted for 32.5%, procedures for 67.5%. At 4 weeks, in subjects with dermatoses, erythema had resolved or improved in 68.0%, desquamation in 83.4%, and irritation in 93.3%. Dryness, burning, itching, and stinging/tingling scores had decreased by 63.8%, 81.8%, 70.9%, and 85.2%, respectively (all P ≤ .0001); 75.7% considered that their skin was sufficiently hydrated. In the procedure group, erythema had resolved or improved in 72.5%, desquamation in 75.2%, and irritation in 88.1%. Dryness, burning, itching, and stinging/tingling scores had decreased by 62.1%, 78.8%, 70.0%, and 84.2%, respectively (all P ≤ .0001); 74.1% considered that their skin was sufficiently hydrated. Almost all subjects reported soothed skin and satisfaction with product texture. Subject and investigator satisfaction was very high. CONCLUSION: M89 significantly improves skin signs and symptoms after 4 weeks of continued use with no tolerance issues in subjects with dermatological indications. Moreover, subjects who have had recently undergone esthetic procedures M89 allowed a satisfying skin recovery.
650    _2
$a aplikace kožní $7 D000279
650    _2
$a dospělí $7 D000328
650    _2
$a kombinovaná terapie $x metody $7 D003131
650    _2
$a kosmetické techniky $x škodlivé účinky $7 D003357
650    _2
$a kosmetické přípravky $x aplikace a dávkování $x škodlivé účinky $x chemie $7 D003358
650    _2
$a obličej $7 D005145
650    _2
$a obličejové dermatózy $x etiologie $x terapie $7 D005148
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kyselina hyaluronová $x aplikace a dávkování $x škodlivé účinky $7 D006820
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a minerální vody $x aplikace a dávkování $x škodlivé účinky $7 D008900
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kůže $x účinky léků $7 D012867
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Spada, Julieta $u Clínica Dra Julieta Spada. Dermatología y Estética, Buenos Aires, Argentina.
700    1_
$a Orlandi, Cecilia $u Clinica Orlandi, Santiago, Chili.
700    1_
$a Kerscher, Martina $u Division of Cosmetic Science, University of Hamburg, Hamburg, Germany.
700    1_
$a Anfilova, Maryna $u Department of Dermatology and Venereology, Vinnytsya National Pirogov Memorial Medical University, Vinnytsya, Ukraine.
700    1_
$a Abdulla, Sonya $u Dermatology on Bloor, Toronto, ON, Canada.
700    1_
$a Floriánová, Adriana $u Private Practice TOMAR, Bratislava, Slovakia.
700    1_
$a Preisz, Klaudia $u Buda Health Centre, Budapest, Hungary.
700    1_
$a Altmayer, Anita $u Department of Dermatology and Allergology, Szent-Györgyi Albert Clinical Centre, Szeged, Hungary.
700    1_
$a Delva, Catherine $u SyliaStat Lancrenon, Bourg-la-Reine, France.
700    1_
$a Kerob, Delphine $u Laboratoires Vichy International, Lavallois Perret, France.
700    1_
$a Goldobina, Maiia $u Private medical practice, Saint-Petersburg, Russia.
700    1_
$a Arenbergerová, Monika $u Department of Dermato-venereology, Third Faculty of Medicine, Charles University, Královské Vinohrady University Hospital, Prague, Czech Republic.
700    1_
$a Tuz, Svyatoslav $u Sharapova Clinic, Samara, Russia.
700    1_
$a Araviiskaia, Elena $u Department of Dermatology, First Pavlov State Medical, University of St. Petersburg, St. Petersburg, Russia.
773    0_
$w MED00007681 $t Journal of cosmetic dermatology $x 1473-2165 $g Roč. 19, č. 3 (2020), s. 682-688
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31793738 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153917 $b ABA008
999    __
$a ok $b bmc $g 1608788 $s 1119633
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 19 $c 3 $d 682-688 $e 20191203 $i 1473-2165 $m Journal of cosmetic dermatology $n J Cosmet Dermatol $x MED00007681
GRA    __
$p Laboratoires Vichy International
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options